Colby Lands Immunotherapy Platform; $140M to MannKind
By Marie Powers
Tuesday, November 13, 2012
Privately held Colby Pharmaceutical Co. continued a wave of wheeling and dealing by paying up to $140 million in up-front and milestone payments to MannKind Corp. for disease-specific antigen compounds and intra-lymph node injection (INLI) technologies from its MKC1106 cancer vaccine program.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.